ASCO GU 2022

Conference Coverage

Cytoreductive Nephrectomy May Improve Survival in ICI-Treated mRCC

In the era of immune checkpoint inhibitors, cytoreductive nephrectomy retains an important role in mRCC in carefully selected patients, according to investigators.

Younger Black Men Have Worst Survival in the mRCC Population

Possible reasons for the survival disparity include differences in obesity and smoking incidence among Black men younger than 50 years.

PD-L1 Expression May Help Predict BCG Response in High-Grade NMIBC

Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.

Cytokines Linked With Survival Outcomes in Nivolumab-Treated mRCC

Validation of the cytokine markers within the entire NIVOREN study is ongoing.

Bladder Cancer Drug Shows Antitumor Activity in Cisplatin-Ineligible Patients

Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.

Early Salvage Radiation After RP Improves Outcomes in Relapsed Prostate Cancer

Early-salvage radiation therapy was associated with reduced risks for biochemical recurrence and metastasis, compared with expectant management.

Sarcopenia Ups Risk for Major mRCC Surgery Complications

Screening for sarcopenia may assist in identifying patients at high risk for increased perioperative morbidity, according to investigators.

Durable Responses to COVID-19 Vaccines Seen in Cancer Patients on Immunotherapy

Patients receiving immunotherapy had a more durable immune response to vaccination, compared with patients receiving chemotherapy or targeted therapy.

No Benefit With Adjuvant Mitotane in Low/Intermediate-Risk Adrenocortical Carcinoma

Adjuvant mitotane does not improve outcomes in patients with adrenocortical carcinoma at low or intermediate risk of relapse after surgery.

Molecular Features of Primary and Metastatic Sites Differ in Renal Cell Carcinoma

New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.

Prostate Radiation Therapy Does Not Affect BCG Efficacy in NMIBC

Intravesical bacillus Calmette-Guérin remains effective in patients with prior radiation treatment for prostate cancer, according to a study.

High-Risk NMIBC Effectively Treated With a BCG Alternative

Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.

Neoadjuvant Abiraterone Prior to Surgery Beneficial in High-Risk Prostate Cancer

In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.

Novel Immunotherapy Plus BCG Effective for Unresponsive Bladder Cancer

The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.

Trimodal Therapy Appears Equivalent to Radical Cystectomy for Select MIBC Patients

The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.

Neoadjuvant Chemotherapy Deemed New Standard Care in Urothelial Carcinoma

The study’s primary endpoint was met, and neoadjuvant chemotherapy was considered well tolerated.

Niraparib Maintenance Failed to Improve Outcomes in Advanced Urothelial Carcinoma

The median progression-free survival was similar between the treatment arms.

AAP Does Not Increase Bone Loss in Metastatic Castration-Sensitive Prostate Cancer

Bone loss was observed in both treatment arms, but abiraterone plus prednisone did not increase bone loss.

Prostate Cancer Screening and Treatment Patterns Differ Across Countries

Compared with German and US patients, UK patients were less likely to be diagnosed with prostate cancer via routine screening.

Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate Cancer

Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer.